1. Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014–2015 to 2016–2017 influenza seasons in Japan
- Author
-
Akemi Koike, Naoko Koseki, Akihito Ishizaka, Yoshio Hatae, Hideaki Kikuta, Akiko Okamura, Katsuki Azuma, Naoko Nagano, Mutsuko Konno, Kohichi Yasoshima, Mari Murashita, Hideto Furuyama, Yoshihiro Kumita, Keisuke Morita, Kyosuke Hazama, Hayato Aoyagi, Keiji Tsubakihara, Kimihiko Takada, Tadashi Ariga, Chie Tobise, Miki Kaiho, Nobuhisa Ishiguro, Akira Tsuchiyama, Takehiro Togashi, Koji Oba, Hideki Arioka, Kazuyuki Uetsuji, Yoko Sawada, Yoshihiro Matsuzono, Kazue Yasuda, Mutsuo Shibata, Shigeru Yamazaki, Yasushi Akutsu, Toru Watanabe, Satoru Shida, Mikio Yoshioka, Tatsuru Yamanaka, Yuuichi Tabata, Akira Inagawa, Nobuaki Kawamura, Akira Tsuchida, and Yasuhisa Odagawa
- Subjects
Male ,0301 basic medicine ,Influenzavirus B ,Influenza A ,Influenza B ,Guanidines ,chemistry.chemical_compound ,0302 clinical medicine ,Japan ,Zanamivir ,Pharmacology (medical) ,030212 general & internal medicine ,Enzyme Inhibitors ,Child ,biology ,virus diseases ,Treatment Outcome ,Infectious Diseases ,Influenza A virus ,Child, Preschool ,Female ,Seasons ,Oseltamivir+Zanamivir ,medicine.drug ,Microbiology (medical) ,Oseltamivir ,medicine.medical_specialty ,Adolescent ,Clinical effectiveness ,030106 microbiology ,Acids, Carbocyclic ,Neuraminidase ,Cyclopentanes ,03 medical and health sciences ,Internal medicine ,Influenza, Human ,medicine ,Humans ,Pyrans ,Laninamivir ,business.industry ,Infant, Newborn ,Infant ,Influenza a ,chemistry ,Sialic Acids ,biology.protein ,Peramivir ,business - Abstract
The clinical effectiveness of four neuraminidase inhibitors (NAIs) (oseltamivir, zanamivir, laninamivir, and peramivir) for children aged 0 months to 18 years with influenza A and B were investigated in the 2014-2015 to 2016-2017 influenza seasons in Japan. A total of 1207 patients (747 with influenza A and 460 with influenza B) were enrolled. The Cox proportional-hazards model using all of the patients showed that the duration of fever after administration of the first dose of the NAI was shorter in older patients (hazard ratio = 1.06 per 1 year of age, p < 0.001) and that the duration of fever after administration of the first dose of the NAI was shorter in patients with influenza A infection than in patients with influenza B infection (hazard ratio = 2.21, p < 0.001). A logistic regression model showed that the number of biphasic fever episodes was 2.99-times greater for influenza B-infected patients than for influenza A-infected patients (p < 0.001). The number of biphasic fever episodes in influenza A-or B-infected patients aged 0-4 years was 2.89-times greater than that in patients aged 10-18 years (p = 0.010), and the number of episodes in influenza A-or B-infected patients aged 5-9 years was 2.13times greater than that in patients aged 10-18 years (p = 0.012).
- Published
- 2018
- Full Text
- View/download PDF